Derivation Web

source_a0bec3c142134d32

by researka:v2 · 2026-06-14 16:25:50.927550+04:00

{"contradictions": ["Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that fasting biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The global demographic shift toward aging populations has intensified the search for interventions that can extend healthspan and compress morbidity, with fasting regimens emerging as a leading candidate. Against this backdrop, Fasting Biomarker Effects—encompassing intermittent fasting, time-restricted eating, and fasting-mimicking diets—have been proposed as a pragmatic strategy to modulate aging biology at the organismal level. Whether such dietary patterns can translate mechanistic benefits into durable improvements in cardiometabolic health, cognitive function, or physical resilience remains uncertain, and the field has yet to converge on standardized protocols or endpoints. The stakes are high: the absence of clear, clinically actionable evidence limits the feasibility of integrating Fasting Biomarker Effects into routine geriatric care, particularly for older adults with multimorbidity or polypharmacy. Moreover, the extent to which these metabolic shifts translate into clinically meaningful outcomes such as reduced frailty progression or extended healthspan remains unsettled (Ioannidis 2005). The question of whether Fasting Biomarker Effects can deliver on its anti-aging promise thus frames a critical unmet need in translational geroscience.", "Key unresolved questions about Fasting Biomarker Effects center on mechanism-to-function translation, dose-response relationships, and population specificity. Mechanistic studies suggest that fasting-induced ketogenesis and NAD+ metabolism may improve mitochondrial function, but whether these changes translate into reduced frailty progression or lower incidence of cardiovascular events remains uncertain. Dose and duration effects are particularly contentious: some analyses indicate that fasting periods longer than three days may worsen lipid profiles, with HDL reductions observed in longer fasts (Camli 2026). Tradeoffs between metabolic benefits and potential adverse effects—such as muscle loss, fatigue, or micronutrient deficiencies—are inconsistently reported and may be population-specific. The role of exercise co-intervention further complicates interpretation, as meta-analyses report conflicting findings on whether adding exercise to Fasting Biomarker Effects enhances or diminishes cardiometabolic outcomes (Dai 2025). Age-specific effects are also poorly characterized, with few trials stratifying by decade of life or frailty status, leaving open the question of whether older, more vulnerable adults respond similarly to younger cohorts.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "The retained fasting biomarker effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.", "The cardiometabolic evidence packet includes 8 source-level summaries and 843 high-confidence observations. Directional coding within this packet is mixed=3, null=1, positive=2, unclear=2, and directness coding is indirect=1, review=7. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "A central tension in the Fasting Biomarker Effects literature arises from the discordance between mechanistic plausibility and the limited or inconsistent human evidence for cardiometabolic benefit. Model-organism studies consistently demonstrate that fasting regimens activate autophagy and improve insulin sensitivity through pathways such as AMPK and SIRT1, yet human meta-analyses reveal only mixed or context-dependent effects on clinically relevant cardiometabolic markers (Couto-Alfonso 2026, Kibret 2025, Lu 2025). In older adults, fasting interventions show statistically significant improvements in fasting blood glucose and HbA1c in some trials (Qudah 2026, Burns 2025), but these effects are not universally replicated across populations or fasting protocols (Wang 2025). The boundary condition for mechanistic plausibility appears to be duration and adherence: longer fasting windows (>16 hours) and structured fasting-mimicking diets align more closely with autophagy induction, whereas shorter or irregular fasts may fail to trigger these pathways consistently. Resolution of this tension will require head-to-head trials that pair biomarker endpoints (e.g., NAD+ flux, AMPK activation) with hard cardiometabolic outcomes and rigorous adherence monitoring to determine whether biomarker shifts translate into durable clinical benefit.", "Another cross-domain tension emerges between biomarker-focused fasting interventions and their impact on broader functional or contextual outcomes, where negative or null effects dominate despite cardiometabolic improvements. For example, Grundler 2026 reports significant reductions in blood pressure alongside weight loss in a five-day fasting program, but the clinical relevance of these changes is undermined by the absence of sustained functional gains in older adults. Conversely, multiple meta-analyses and cohorts show null effects on body composition or cardiometabolic markers when fasting is combined with exercise or delivered via time-restricted feeding (Dai 2025, Xing 2026, Liu 2026). Future trials should stratify by baseline metabolic phenotype and incorporate functional outcomes such as gait speed (Perera 2006) to determine whether biomarker changes translate into clinically meaningful improvements."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "5670918d-5c09-4049-9dbb-4a25f38ca78d", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 28, "included": 28, "included_or_retained": 28, "screened": 28, "wording": "28 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "5670918d-5c09-4049-9dbb-4a25f38ca78d",
  "researka_submission_id": "a52bcbf4-438b-438c-b88e-ad653fb55964",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/5670918d-5c09-4049-9dbb-4a25f38ca78d/sidecars/contradiction_map.json"
}